Aquestive Therapeutics, Inc.
Company Stats
- Market Cap
- $581.1M
- as of Sep 30, 2026
- Shares Outstanding
- 125.5M
- Free Float
- 91.7%
Income Statement
- Revenue
- $44.5M
- Operating Income
- -$71.1M
- Net Income
- -$83.8M
- EBITDA
- -$70.5M
- Revenue Growth, 3Y
- -2.2%
- FCF Margin, 3Y Avg
- -65.3%
- FCF Margin, Worst Year
- -119.0%
Cash Flow
- Free Cash Flow
- -$53.0M
- FCF Yield
- -9.1%
- Owner FCF Yield
- -10.4%
Returns & Capital
- SBC, 3Y Avg
- $5.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $44.5M | -$53.0M | -119.0% |
| FY2024 | $57.6M | -$35.9M | -62.4% |
| FY2023 | $50.6M | -$7.4M | -14.6% |
| FY2022 | $47.7M | -$10.8M | -22.7% |
| FY2021 | $50.8M | -$33.9M | -66.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Micro-Cap Deals Roundup for Week of Oct. 12, 2026
Stronger demand supports expansion as pricing diverges